Search Results 61-70 of 16550 for B cell lymphomas
CD20+Diffuse Large B-Cell Lymphoma. · Ann Arbor stage 3 or 4 or stage 2 with bulky disease · High or high-intermediate disease risk. · No prior anti-lymphoma ...
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem ...
An Effectiveness and Safety Study of Daratumumab in Relapsed/Resistant Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. Print ...
In B-cell non-Hodgkin's lymphoma, cells other than tumor cells are commonly seen within tumor tissue. These cells include T lymphocytes that seem to be more ...
... B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL). Participation eligibility.
The purpose of tis study is to evaluate whether adding brentuximab vedotin helps two drugs work better to treat patients with diffuse large B-cell lymphoma ( ...
... lymphoma or B-cell acute leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by ...
ZUMA-7 led to the approval of axicabtagene ciloleucel for second line treatment of large B-cell lymphoma after showing better outcomes compared with ...
... cell lymphoma, a subset of B-cell lymphoma. It was also approved in February 2014 for use in CLL, following a study of the agent alone in patients with very ...
... lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL) ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.